advances in managing krasg12c- and egfr-mutated nsclc
Published 2 years ago • 97 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
2:47
etop clinical trials in egfr-, krasg12c- and alk-mutated nsclc
-
2:12
advances in the management of kras-mutant nsclc
-
1:10
current treatment strategies krasg12c–mutated nsclc
-
1:41
physician perceptions of testing practices in patients with egfr mutated nsclc
-
5:03
understanding nsclc treatment when you have an egfr mutation
-
3:01
update from chrysalis: amivantamab in patients with nsclc with met exon 14 skipping mutation
-
7:46
personalized therapies for patients with kras-mutant lung cancer
-
4:17
nsclc trial updates at esmo 2022: adaura, destiny-lung02, kn189, kn407 & poseidon
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
1:02:40
new milestones and changing standards of care in early egfr-mutated nsclc
-
1:37
treatment strategies for kras-mutant nsclc with co-mutations
-
1:22
recent advances in targeted agents for the treatment of lung cancer
-
1:02:05
adjuvant egfr-targeted therapy as a game changer in multimodal nsclc management
-
1:04
molecular testing in egfr mutant driven nsclc
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
0:58
kras g12c inhibitors for gi cancer
-
3:17
krystal-1: activity of adagrasib in krasg12m nsclc with untreated cns metastases
-
3:14
advancements of targeted therapy for egfr mutations in nsclc
-
2:21
treatment of egfr nsclc after progression
-
0:47
the role of immunotherapy with kras inhibitors in kras-driven nsclc
-
37:44
deciphering the data in egfr - mutant nsclc